Optimal Prescribing to Enhance Mobility Among Seniors: A GeriMedRisk-TAPERMD collaboration
Multiple diseases, multiple medications, and age predispose seniors to drug toxicity, which increases the risk of mortality, and impairs mobility and cognition. GeriMedRisk-TAPERMD is a comprehensive, multilevel approach to polypharmacy that integrates a geriatric pharmacology consultation service and a clinical pathway for systematic medication reduction. This pathway incorporates teamwork between patients, pharmacists and physicians. It integrates patient priorities, electronic screening for potentially harmful medicines, supporting evidence, tools and a monitoring pathway to support medication reduction. This project will:
- Examine the feasibility of GeriMedRisk-TAPERMD in the long-term care setting.
- Assess GeriMedRisk-TAPERMD’s potential to decrease drug-related hospital visits and falls.
- Assess the potential for reversal of polypharmacy-associated mobility impairment following deprescribing using the TAPERMD clinical pathway.
Dee Mangin, Julie Richardson, Joanne Ho and Jobin Varugese are leading the assessment of the detailed effects of the TAPERMD-GeriMedRisk clinical pathway on mobility outcomes.
Investigators
Co-Principal Investigators:
- Dee Mangin
- Joanne Ho
Co-Investigators:
- Julie Richardson
- Andrew Costa
- Gordon Guyatt
- Anne Holbrook
- Reza Mirza
- Justin Lee
- Lehana Thabane
- Jobin Varughese
